. Author manuscript; available in PMC: 2016 Jan 21.

Published in final edited form as: Expert Rev Vaccines. 2014 Mar;13(3):387–398. doi: 10.1586/14760584.2014.880340

Table 2.

Key qualitative and quantitative differences between SA-4-1BBL and agonistic 4-1BB antibodies

Immune responses altered	SA-4-1BBL	Agonistic 4-1BB Abs	References
Generation of primary T cell responses	++	+	4,11,12,17
CD8⁺ T cell proliferation	++	+	11
CD4⁺ T cell proliferation	++	+	11
Super agonist for naive T cells	−	+	11, 62
Generation of CD8⁺CD11c⁺ T cells	−	+	59, unpublished observations
CD4⁺CD25⁺FoxP3 Treg cell expansion in vitro	+	+	17, 57
CD4⁺CD25⁺FoxP3 Treg cell expansion in vivo	−/+	++	11, 56
Inhibition of CD4⁺CD25⁺FoxP3⁺ Treg cell suppression	Endows CD4⁺ T effectors resistant to suppression by Treg cells	Endows CD4⁺ T effectors resistant to suppression by Treg cells, direct inhibition of Treg function	4, 17, 70
Inhibition of T effector conversion into CD4⁺CD25⁺FoxP3⁺ Treg cells	+	?	10
Immune abnormalities	None observed	Splenomegaly, lymphadenopathy, hepatomegaly, multifocal hepatitis, lymphopenia, thrombocytopenia, anemia, systemic cytokine release, excessive T cell proliferation, altered trafficking of B cells and CD8⁺ T cells, loss of NK and B cells, inhibition of Ab response	11, 62, 63,64
Efficacy for tumor eradication	++	+	4,5,12,14